Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

EO-3021

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

CSPC Pharma, Elevation Oncology

Drug class:

Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate

Related drugs:

‹

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

enfortumab vedotin-ejfv (14)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

PF-08046048 (4)

PF-08046047 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

›

CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	EO-3021 Sensitive: B - Late Trials Elevation Oncology Press Release - 4 weeks (New B) EO-3021 Sensitive : B Elevation Oncology Press Release - 4wk	EO-3021 Sensitive: B - Late Trials Elevation Oncology Press Release - 4 weeks EO-3021 Sensitive : B Elevation Oncology Press Release - 4 weeks - (New B)
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	EO-3021 Sensitive: B - Late Trials Elevation Oncology Press Release - 4 weeks (New B) EO-3021 Sensitive : B Elevation Oncology Press Release - 4wk	EO-3021 Sensitive: B - Late Trials Elevation Oncology Press Release - 4 weeks EO-3021 Sensitive : B Elevation Oncology Press Release - 4 weeks - (New B)
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Lung Cancer	CLDN18.2 expression	Lung Cancer	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2